Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Loveless

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Practical Neurology|June 28, 2019
Using biomarkers to predict clinical outcomes in multiple sclerosisDaniel Castle, Ray Wynford-Thomas, Sam Loveless, et al.
Journal of Neuroimmunology|May 27, 2026
Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosisTarunya Arun, W John Watkins, Kirsten Baillie, et al.
Acta Neuropathologica Communications|June 3, 2014
Complement activation in multiple sclerosis plaques: an immunohistochemical analysisGillian Ingram, Sam Loveless, Owain W Howell, et al.
Brain : a Journal of Neurology|April 28, 2010
Complement regulator factor H as a serum biomarker of multiple sclerosis disease stateGillian Ingram, Svetlana Hakobyan, Claire L Hirst, et al.
Brain, Behavior, and Immunity|February 25, 2026
Bloodstream infections and Blood-Brain barrier Permeability: An observational cohort studyJonathan Underwood, Kate Davies, Sam Loveless, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2018
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59Wioleta M Zelek, Lewis M Watkins, Owain W Howell, et al.
Journal of Neuroinflammation|February 17, 2024
Combination protein biomarkers predict multiple sclerosis diagnosis and outcomesEleftheria Kodosaki, W John Watkins, Sam Loveless, et al.
Annals of Neurology|November 17, 2023
Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real-World CohortKarim L Kreft, Emeka Uzochukwu, Sam Loveless, et al.
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Multiple Sclerosis and Related Disorders|August 3, 2024
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administrationLiza M Y Gelissen, Sam Loveless, Alyssa A Toorop, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Practical Neurology|June 28, 2019
Using biomarkers to predict clinical outcomes in multiple sclerosisDaniel Castle, Ray Wynford-Thomas, Sam Loveless, et al.
Journal of Neuroimmunology|May 27, 2026
Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosisTarunya Arun, W John Watkins, Kirsten Baillie, et al.
Acta Neuropathologica Communications|June 3, 2014
Complement activation in multiple sclerosis plaques: an immunohistochemical analysisGillian Ingram, Sam Loveless, Owain W Howell, et al.
Brain : a Journal of Neurology|April 28, 2010
Complement regulator factor H as a serum biomarker of multiple sclerosis disease stateGillian Ingram, Svetlana Hakobyan, Claire L Hirst, et al.
Brain, Behavior, and Immunity|February 25, 2026
Bloodstream infections and Blood-Brain barrier Permeability: An observational cohort studyJonathan Underwood, Kate Davies, Sam Loveless, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2018
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59Wioleta M Zelek, Lewis M Watkins, Owain W Howell, et al.
Journal of Neuroinflammation|February 17, 2024
Combination protein biomarkers predict multiple sclerosis diagnosis and outcomesEleftheria Kodosaki, W John Watkins, Sam Loveless, et al.
Annals of Neurology|November 17, 2023
Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real-World CohortKarim L Kreft, Emeka Uzochukwu, Sam Loveless, et al.
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Multiple Sclerosis and Related Disorders|August 3, 2024
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administrationLiza M Y Gelissen, Sam Loveless, Alyssa A Toorop, et al.
Pageof 2